Actively Recruiting
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
Led by Third Affiliated Hospital, Sun Yat-Sen University · Updated on 2024-03-01
200
Participants Needed
1
Research Sites
369 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.
CONDITIONS
Official Title
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Positive hepatitis B surface antigen and hepatitis B antibody for more than 0.5 year
- Age from 18 to 65 years old
- Serum Alanine Aminotransferase (ALT) ≤1×ULN for at least 12 weeks
- Positive Hepatitis B virus (HBV)
- No nucleotide/nucleoside analogues or interferon treatment in the past 6 months
You will not qualify if you...
- Other active liver diseases
- Hepatocellular carcinoma or other malignancy
- Pregnancy or lactation
- Human immunodeficiency virus infection or congenital immune deficiency diseases
- Severe diabetes or autoimmune diseases
- Other important organ dysfunctions
- Using glucocorticoid
- Inability to follow-up
- Investigator considers participation inappropriate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510630
Actively Recruiting
Research Team
Q
Qiumin Luo, Doctor
CONTACT
L
Liang Peng, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here